ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
News|Articles|October 4, 2023
Novartis Launches Sandoz Spinoff, Creating Independent Company
Separate entity allows company to concentrate on status as focused medicines company.
Advertisement
Novartis has officially completed the spinoff process for Sandoz, its generics and biosimilars division, with each shareholder receiving one Sandoz share for every five Novartis shares or one Sandoz American Depositary Receipt (ADR) for every five Novartis ADRs. In the future, Novartis intends to become solely a focused medicines company.
“This is a truly historic moment for Novartis and Sandoz, as we begin new chapters as independent companies. With several consecutive quarters of sales growth, Sandoz starts out from a position of strength as a global leader in Generics and Biosimilars, and I am confident they are poised to deepen their impact on patients and society,” said Vas Narasimhan, MD, CEO, Novartis. “Today, after more than USD 100bn in transactions over the last few years, Novartis emerges as a fully focused innovative medicines company. We are entering this new era with strong financial performance and R&D momentum, and I’m more confident than ever in our ability to reimagine medicine for and with patients around the globe.”
Reference: Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company. Novartis. October 4, 2023. Accessed October 4, 2023. https://www.novartis.com/news/media-releases/novartis-executes-sandoz-spin-completing-strategic-transformation-leading-focused-innovative-medicines-company
Advertisement
Related to this article
Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.
Advertisement
Advertisement
Trending on PharmExec
1
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
2
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
3
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
4
Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie
5